Held in San Antonio, Texas, from the 10th to the 14th of November, this meeting will provide delegates with the opportunity to see some of the latest developments in the pharmaceutical sector, including a variety of projects which have benefitted from the reduced costs and faster time-to-market offered by Quotient Clinical’s innovative development platform.
Quotient Clinical will be supporting several other activities and events at the meeting, including a RapidFACT™ user group meeting and six poster presentations. The RapidFACT user meeting will aim to build on last year’s highly successful event, and will include a number of customer presentations, as well as an open forum to discuss various aspects of the RapidFACT process. On the final day of the conference, Dr Alyson Connor, Director of Exploratory Clinical Pharmacology at Quotient Clinical, will be participating in a symposium featuring a number of prominent speakers from academia and industry entitled Understanding in vivo dissolution: can imaging tools provide the missing link? Alyson will be discussing the practicalities of tracking oral dosage form performance using scintigraphic imaging, and participating in a panel discussion on the use of imaging tools in pharmaceutical research.
To learn more about Translational Pharmaceutics and how the Quotient Clinical approach can significantly reduce the time and cost ofbringing a drug to market, visit booth 2800 or go to www.quotientclinical.com
About Quotient Clinical
Quotient Clinical has over 20 years’ experience delivering high quality data to provide innovative early drug development solutions to pharmaceutical and biotechnology clients worldwide, including 17 of the top 20 pharmaceutical companies. Our expertise in Exploratory Clinical Pharmacology,Drug Product Optimisation, and 14C Enabled Drug Development, underpinned by our unique Translational Pharmaceutics™
and Synthesis-to-Clinic™ delivery platforms, adds significant value to client development programs.
_______________________________________________